3.52
+14.66%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Corbus Pharmaceuticals Holdings
From its filings with the US Securities and Exchange Commission
Corbus Pharmaceuticals Holdings is based in Norwood, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CRBP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $0.
All references in this report to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.
Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE") and CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity.
CRB-701 (SYS6002) is a novel clinical stage ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of MMAE. In February 2023, the Company obtained a license from CSPC Megalith Biopharmaceutical Co. Ltd. (“CSPC”), a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States (“U.S.”), Canada, the European Union (including the European Free Trade Area), the United Kingdom (“U.K.”) and Australia. The Company is conducting a Phase 1/2 study in the U.S. and Europe (the "Western study") enrolling patients with advanced solid tumors associated with Nectin-4 expression. The dose expansion phase of the clinical trial is ongoing.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Oct 2014
- Employees
- 36
- Website
- corbuspharma.com ↗
- Head office
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Rachelle JacquesIndependent Chairman of the Board, since 2019$288,824
- Dr. Yuval CohenChief Executive Officer, Director, since 2014$4.2m
- Mr. Sean MoranChief Financial Officer$2.4m
- Dr. Ian HodgsonChief Operating Officer
- Dr. Dominic SmethurstChief Medical Officer$2.9m
- Dr. Anne AltmeyerIndependent Director$276,324
- Dr. Yong BenIndependent Director$276,657
- Mr. Alan HolmerIndependent Director$298,824
- Dr. John JenkinsIndependent Director$293,824
- Mr. Winston KungIndependent Director$584,395
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 45
- Social
- 17
- Governance
- 53
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Corbus Pharmaceuticals focuses on phase 3 clinical-stage therapeutics for rare inflammatory diseases in the Health Care sector.
- Lenabasum is a novel oral endocannabinoid-mimetic drug targeting chronic inflammation and fibrosis.
- The company develops lenabasum for four specific diseases including systemic sclerosis and SLE.
Weaknesses
- Corbus has only 36 employees in the US market, a small team for clinical development.
- The company's lead product lenabasum is still in phase 3 clinical trials.
- Corbus operates with a limited commercialization segment for rare diseases.
Opportunities
- The US market offers opportunities for rare disease therapeutics in Health Care.
- Lenabasum's potential to treat systemic sclerosis could expand market reach.
- Corbus can leverage phase 3 clinical results to attract investors.
Threats
- The US regulatory environment poses challenges for biotechnology clinical trials.
- Competition in the Health Care sector for rare disease treatments is increasing.
- Lenabasum's phase 3 trials may face delays or failure.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.